Compound having oxadiazole and pharmaceutical composition containing the same
Inventors
RYU, Choon Ho • Han, Min Soo • Yoon, Yeo Jin • KIM, Yu Jin • LEE, Ka Eun • Lee, Ju Young • Jung, Myung Jin • BAEK, Eun Hee • SHIN, Yu Jin • Choi, Eun Ju • Kang, Young Soon • Kim, Yong Soo • SONG, Yea Mi • Kim, Jin Sung • LIM, Hee Jeong
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12145914-B2
Publication Date
2024-11-19
Expiration Date
Abstract
Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.
Core Innovation
The invention provides Chemical Formula 1 compounds, including optical isomers, stereoisomers, and pharmaceutically acceptable salts thereof, as analogs of a fluoro-substituted phenyl-(5-methyl-1,3,4-oxadiazol-2-yl)ethanol scaffold. The described structural variation includes substituents on the phenyl ring, including trifluoromethoxy, trifluoroethoxy, trifluorobutoxy, butoxy, propoxy, longer alkyl substituents, and trifluorinated alkyl groups, and also includes carbamates and a benzamide form.
The invention is directed to treating epilepsy by administering a therapeutically effective amount of a Chemical Formula 1 compound, or an optical isomer, stereoisomer, or pharmaceutically acceptable salt thereof. A pharmaceutical composition is also provided that includes a therapeutically effective amount of a Chemical Formula 1 compound and a pharmaceutically acceptable carrier, with the formula defining substituent variables and integer ranges that constrain the chemical structure.
The patent content includes experimental evaluation of anticonvulsant activity in a 6-Hz refractory focal onset seizure model, with protection-rate scoring and comparison to reference anticonvulsant standards including levetiracetam, topiramate, and lamotrigine. The scope of the text centers on substituted oxadiazole-containing ethanol derivatives and corresponding carbamate derivatives, with structure-variant coverage within the described formula space by changing phenyl-ring substituents and by switching between carbamate and benzamide derivatization.
Claims Coverage
The independent claims comprise two inventive concepts: a method for treating epilepsy by administering Chemical Formula 1 and a pharmaceutical composition containing a therapeutically effective amount of Chemical Formula 1 with a pharmaceutically acceptable carrier. Across the independent claims, the core inventive coverage is the constrained Chemical Formula 1 chemical space defined by R1–R9, X/Y/Z, and integer ranges m, n, o, p, and q. There are 2 inventive features.
Treating epilepsy by administering Chemical Formula 1
Administering to a subject in need thereof a therapeutically effective amount of Chemical Formula 1, or an optical isomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound structure is defined by R1–R9 substituent selections, X/Y/Z, and integer ranges m, n, o, p, and q.
Pharmaceutical composition with Chemical Formula 1 and pharmaceutically acceptable carrier
Providing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the compound structure is defined by R1–R9 substituent selections, X/Y/Z, and integer ranges m, n, o, p, and q.
Claim coverage centers on the constrained Chemical Formula 1 structural space and its use for treating epilepsy, either as a method of administration to a subject or as a pharmaceutical composition with a pharmaceutically acceptable carrier.
Stated Advantages
Provides anticonvulsant effect in a 6-Hz refractory focal onset seizure animal model.
Anticonvulsant/antiepileptic advantage in a 6-Hz refractory focal onset seizure model compared with levetiracetam, topiramate, and lamotrigine.
Documented Applications
Treatment of epilepsy by administering Chemical Formula 1, or optical isomer, stereoisomer, or pharmaceutically acceptable salt thereof, to a subject in need thereof.
Use of Chemical Formula 1 showing anticonvulsant effect in a 6-Hz refractory focal onset seizure animal model.
Use of Chemical Formula 1 in a 6-Hz refractory focal onset seizure model for anticonvulsant/antiepileptic evaluation.
Formulating a pharmaceutical composition containing a Chemical Formula 1 compound with a pharmaceutically acceptable carrier.
Interested in licensing this patent?